Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Padia on the Utility of Y-90 Glass Microspheres in HCC

June 5th 2021

Siddharth Padia, MD, discusses the utility of TheraSphere™ Yttrium-90 Glass Microspheres in patients with hepatocellular carcinoma.

Frontline Nivolumab Plus Ipilimumab or Chemo Improves Survival Outcomes in Advanced ESCC

June 3rd 2021

The addition of nivolumab to either ipilimumab or chemotherapy resulted in improved survival outcomes vs chemotherapy alone in the frontline treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.

TheraSphere Proves Highly Effective in HCC

June 3rd 2021

Siddharth Padia, MD, explaines TheraSphere’s unique mechanism of action and what its approval means in HCC and beyond.

Derazantinib Continues to Elicit Encouraging Responses in FGFR2 Gene Fusion–Positive Intrahepatic Cholangiocarcinoma

June 2nd 2021

Derazantinib continued to induce encouraging responses in patients with FGFR2 gene fusion–positive intrahepatic cholangiocarcinoma, according to updated data from cohort 1 of the phase 2 FIDES-01 trial.

Innovation Fuels Breakthroughs for Rare Cancers

June 2nd 2021

Innovative strategies are vital for patients diagnosed with rare cancers, who are frequently at a disadvantage compared with those who have more common malignancies, experts say.

Neoadjuvant Cemiplimab Induces Tumor Necrosis in Resectable HCC

June 1st 2021

Parissa Tabrizian, MD, MSc, discusses the rationale for evaluating cemiplimab in the neoadjuvant setting for patients with resectable hepatocellular carcinoma, the results of the trial, and next steps planned to identify optimal clinical end points that correlate with survival benefit.

Dr. Javle on the FDA Approval of Infigratinib in FGFR-Mutated Cholangiocarcinoma

May 28th 2021

Milind Javle, MD, discusses the FDA approval of infigratinib in FGFR-mutated cholangiocarcinoma.

FDA Approves Infigratinib for FGFR2+ Cholangiocarcinoma

May 28th 2021

The FDA has approved infigratinib for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Uboha Underscores Latest Breakthroughs in Gastrointestinal Cancers

May 28th 2021

Nataliya V. Uboha, MD, PhD, zeros in on the developments with ADCs and monoclonal antibodies in gastric cancer and recent changes in pancreatic cancer as key takeaways from the event.

Research Collaboration Aims to Bring TLR9 Agonist SD-101 to Patients With Pancreatic and Liver Cancer

May 27th 2021

The University of Texas MD Anderson Cancer Center and the immuno-oncology company TriSalus™ Life Sciences announced a strategic research collaboration to evaluate SD-101 in pancreatic cancer and hepatocellular carcinoma.

Cemiplimab Granted Positive EU Opinion for Advanced NSCLC and Basal Cell Carcinoma

May 24th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of cemiplimab for use in 2 advanced cancers: non–small cell lung cancer and basal cell carcinoma.

Frontline Pembrolizumab/Chemo Recommended for EU Approval for Select Esophageal or HER2-Negative GEJ Adenocarcinoma

May 24th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of pembrolizumab plus platinum- and fluoropyrimidine-based chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic esophageal carcinoma or HER2-negative gastroesophageal junction adenocarcinoma with PD-L1 positivity.

Maintenance Rucaparib Shows Efficacy in Advanced Pancreatic Cancer Harboring BRCA1, BRCA2, or PALB2

May 20th 2021

The PARP inhibitor rucaparib has proven to be a safe and effective maintenance option for patients with platinum-sensitive, advanced pancreatic cancer that harbors pathogenic variants such as BRCA1, BRCA2, or PALB2.

FDA Approves Adjuvant Nivolumab for Resected Esophageal or GEJ Cancer

May 20th 2021

The FDA has approved nivolumab for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, in patients have received neoadjuvant chemoradiotherapy.

Dr. Sanjeevaiah on the Benefit of Immunotherapy Agents in Gastric Cancers

May 17th 2021

Aravind R. Sanjeevaiah, MD, discusses the benefit of immunotherapy agents in the treatment of patients with gastric cancers.

Zolbetuximab Plus EOX Improves Survival in Claudin 18.2+ Gastric/GEJ Cancers

May 17th 2021

The addition of the first-in-class chimeric monoclonal antibody zolbetuximab to frontline epirubicin, oxaliplatin, and capecitabine chemotherapy resulted in prolonged progression-free survival and overall survival compared with EOX alone in patients with advanced Claudin 18.2-positive gastric and gastroesophageal junction adenocarcinoma, according to the primary results of the phase 2 FAST trial.

Role of Adjuvant Chemoradiation Under Study in Gastric Cancer

May 16th 2021

Katelyn M. Atkins, MD, PhD, examines the evolving role of radiotherapy in the treatment of patients with gastric cancer, the subgroups who might derive the most benefit from this approach, and ongoing research efforts that are seeking to address remaining questions with this modality.

Gong Gives Perspective on Sequencing Challenges Faced in Advanced HCC

May 14th 2021

Jun Gong, MD, discusses the impact of the IMbrave150 trial on the advanced HCC treatment paradigm and challenges faced with sequencing.

Personalized, Adaptable Treatment Strategies May Improve Survival in Metastatic Gastroesophageal Cancer

May 12th 2021

Offering patients with metastatic gastroesophageal tumors a more personalized and adaptable treatment approach using monoclonal antibodies matched to genetic profiles in combination with chemotherapy may result in higher rates of survival compared with historic controls.

Rapid Readouts: A Global Study of Advanced Dosimetry in the Treatment of HCC With Y 90 Glass Microspheres

May 12th 2021

Riad Salem, MD, presents slides supporting global real-world data confirming a significant association between tumor-absorbed dose, objective response between tumor-absorbed dose and overall survival in patients with hepatocellular carcinoma (HCC) treated with yttrium-90 glass microspheres.